CCRM’s Cell & Gene Therapies 101 (www.cgt101.ca) will offer an introduction to the steps involved in manufacturing a cell and/or gene therapy product and taking it through to clinical trials and beyond. The workshop will include a case study exercise, a fireside keynote talk, lectures and interactive panel discussions. This two-day event, taking place Nov. 8-10 in Mont-Tremblant, is tailored to postdoctoral fellows, PhDs/MScs, new PIs and early-stage biotech companies.
Confirmed expert speakers, and the topics they will cover, are listed below:
- A fireside keynote talk with Robert Deans, Chief Technology Officer, BlueRock Therapeutics
- Nick Timmins, VP Process Sciences, BlueRock Therapeutics, on the 5Ws of cell and gene therapies
- Steven Keizer, Senior Quality Manger, CCRM, on manufacturing principles
- Aaron Dulgar-Tulloch, Director, [email protected], GE Healthcare, on scale-up and scale-out framework fundamentals
- Denis Claude Roy, Director, Centre de recherche de l’Hôpital Maisonneuve-Rosemont, on preclinical studies needed to get a cell/gene therapy into the clinic
- Sowmya Viswanathan, Affiliate Scientist, Krembil Research Institute (University Health Network) on dosing and efficacy in Phase 0-III trials
- Francisca Agbanyo, Chief of Blood, Cells, Tissues and Organs Division, Health Products and Food Branch, Health Canada, Government of Canada, with a regulatory overview
- Chris McCabe, Executive Director & CEO, Institute of Health Economics, on reimbursement 101
Join in on the conversation with Laine Jaremey when you subscribe to Toronto Health.